Data from Baez-Jurado and Rincón-Benavides (2019) and others reveal that ER-β activation reduces amyloidogenic processing, dampens microglial priming, and improves mitochondrial efficiency—mechanisms that align with inflammation-associated treatment resistance in chronic mood disorders (77–79). The gene discussed is ESR2; the disease is mood disorder.